How to Get Repatha (Evolocumab) in Wyoming

What Is Repatha and Why Wyoming Patients Need It

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. By blocking PCSK9, evolocumab allows more LDL receptors to remain active, driving LDL-C out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1].

Wyoming has one of the lower physician-to-patient ratios in the United States. The state's frontier geography means cardiologists are concentrated in Cheyenne, Casper, and Jackson, leaving patients in Sublette, Niobrara, and Goshen counties with limited face-to-face specialist access. Telehealth closes that gap. Wyoming law explicitly permits prescribing via synchronous audiovisual telemedicine, including Schedule-exempt medications such as evolocumab [2].

The landmark FOURIER trial (N=27,564) demonstrated that adding evolocumab 140 mg every 2 weeks to optimized statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL [3]. The trial also showed a 15% relative risk reduction in the composite cardiovascular endpoint (cardiovascular death, MI, stroke, unstable angina, or coronary revascularization) at a median follow-up of 2.2 years [3]. For Wyoming patients with established ASCVD carrying LDL-C above 70 mg/dL on maximally tolerated statin therapy, that reduction can be the difference between a second event and continued stability.

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states that PCSK9 inhibitors are recommended (Class I, LOE A) for very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe [4].

Who Qualifies for a Repatha Prescription in Wyoming

Qualifying for evolocumab requires one of three FDA-approved indications. Patients must have a confirmed diagnosis before any prescriber, telehealth or in-person, can write the prescription.

Heterozygous familial hypercholesterolemia. HeFH affects approximately 1 in 250 adults in the U.S. [5]. Diagnosis rests on Dutch Lipid Clinic Network (DLCN) criteria or a confirmed pathogenic LDLR, APOB, or PCSK9 variant. Wyoming patients meeting DLCN criteria of 6 or more points qualify. A genetic test is not required by the FDA label, but many commercial insurers in Wyoming demand it or require a lipid specialist note confirming clinical criteria before approving PA.

Homozygous familial hypercholesterolemia. HoFH affects roughly 1 in 300,000 individuals. LDL-C at baseline commonly exceeds 400 mg/dL. These patients typically require subspecialty referral, and most Wyoming cases are managed in coordination with University of Utah or Denver Health lipid clinics via telehealth co-management.

Established ASCVD. This is the most common pathway for Wyoming patients. Qualifying events include prior MI, ischemic stroke, symptomatic peripheral arterial disease, or coronary revascularization. The ACC/AHA 2022 guidelines further stratify "very high risk" as two or more major ASCVD events, or one major event plus two or more high-risk conditions (diabetes, hypertension, chronic kidney disease, current smoking, or LDL-C persistently above 100 mg/dL) [4].

Patients whose only lipid abnormality is elevated triglycerides or isolated low HDL-C do not qualify for the FDA-labeled indications and will not receive prior-authorization approval under standard Wyoming commercial plans.

Labs Required Before Starting Repatha in Wyoming

A fasting lipid panel is the minimum laboratory requirement. Wyoming providers, including telehealth prescribers, need a baseline LDL-C drawn within the past 90 days to demonstrate the residual elevation that justifies prescribing. Most PA forms require documentation that the patient has been on maximally tolerated statin therapy for at least 4 weeks before the lipid panel was drawn [6].

The following lab set constitutes a complete pre-prescription workup, per the National Lipid Association's 2023 recommendations [6]:

1. Fasting lipid panel (total cholesterol, LDL-C, HDL-C, non-HDL-C, triglycerides). Fasting for 9-12 hours before the draw improves LDL-C accuracy, particularly when triglycerides exceed 200 mg/dL.
2. Comprehensive metabolic panel (CMP). Baseline hepatic function (AST, ALT) and renal function (creatinine, eGFR) allow detection of any contraindication to continued statin therapy and establish a reference point for monitoring.
3. Lipoprotein(a). Lp(a) above 50 mg/dL (or 125 nmol/L) independently raises ASCVD risk and strengthens the clinical case for PCSK9 inhibition. The European Atherosclerosis Society recommends at least one lifetime Lp(a) measurement in every adult [7]. While not required by the FDA label, submitting an elevated Lp(a) result with a PA request can support medical necessity in borderline cases.
4. HbA1c or fasting glucose. Relevant if the patient has diabetes as a comorbidity, since diabetes is a high-risk modifier under ACC/AHA criteria [4].
5. TSH. Hypothyroidism elevates LDL-C independently. Undiagnosed hypothyroidism treated with levothyroxine can lower LDL-C enough to eliminate need for Repatha, so confirming euthyroid status before initiating an expensive biologic is good clinical practice.

Labs can be drawn at any CLIA-certified laboratory in Wyoming, including Cheyenne Regional Medical Center's outpatient lab, Casper's Wyoming Medical Center lab, or national networks such as LabCorp and Quest Diagnostics, which have draw sites in Laramie, Gillette, and Rock Springs [8]. Telehealth platforms typically generate a lab order electronically; patients present the order at any in-network draw site.

How Telehealth Prescribing Works for Repatha in Wyoming

Wyoming enacted its telehealth coverage parity law under W.S. 26-15-144, requiring insurers to reimburse telehealth services at parity with in-person equivalents. Prescribers licensed in Wyoming may write a Repatha prescription following a synchronous audiovisual visit without a prior in-person examination, provided they can establish a valid prescriber-patient relationship [2].

The workflow through a HealthRX telehealth visit follows five steps.

Step 1: Schedule. Book a cardiovascular-risk or lipid-management visit. No in-office travel required.

Step 2: Upload records. Before the visit, upload your most recent lipid panel, documentation of your qualifying diagnosis (discharge summary, cardiology note, or genetic report), and a list of current medications confirming statin therapy.

Step 3: Synchronous visit. A Wyoming-licensed physician, NP, or PA conducts a live audiovisual review of your history, labs, and cardiovascular risk. Under Wyoming statute, nurse practitioners with full-practice authority may prescribe evolocumab without a physician co-signature [9]. Physician assistants prescribe under a collaborative agreement with a supervising physician.

Step 4: Prescription and PA filing. If clinically appropriate, the prescriber sends the prescription electronically to your specialty pharmacy and initiates the prior-authorization request to your insurer.

Step 5: Specialty pharmacy coordination. Repatha ships from specialty pharmacies such as CVS Specialty, Walgreens Specialty, or Accredo. These pharmacies are licensed to ship to Wyoming addresses. Expect 7-21 days from prescription date to delivery when PA is required.

A 2021 analysis in JAMA Internal Medicine found that telehealth visits for cardiovascular risk management produced lipid-panel follow-up rates statistically equivalent to in-person care (76.3% vs. 74.8%, P = 0.41) in a rural-patient cohort [10]. Wyoming's frontier population fits that demographic closely.

Prior Authorization in Wyoming: What Commercial Plans Require

Prior authorization is nearly universal for Repatha in Wyoming. Both commercial plans and marketplace plans sold through Wyoming's exchange require PA before dispensing. The documentation package your prescriber must assemble typically includes the following elements, derived from Wyoming's major payer criteria (BlueCross BlueShield of Wyoming, UnitedHealthcare, Cigna, and Aetna step-therapy requirements as of 2024) [11]:

• Documented qualifying diagnosis (ICD-10 code: E78.01 for HeFH, E78.02 for HoFH, or I25.10 for established coronary artery disease)
• Current LDL-C result with date, drawn on stable maximally tolerated statin therapy
• Statin therapy history, including the specific statin, dose, and duration; if statin-intolerant, documentation of at least two trial failures with documented adverse effects
• Evidence of ezetimibe trial (most Wyoming commercial plans require at least a 3-month trial of ezetimibe 10 mg before approving Repatha)
• Prescriber specialty or, for primary-care prescribers, a lipid-specialist consultation note

The average PA decision time for PCSK9 inhibitors under Wyoming commercial plans is 14 days for standard review. Expedited review (72 hours) applies when the treating physician documents imminent clinical risk, such as a recent ACS hospitalization within 90 days [12].

If the initial PA is denied, Wyoming insurers are required by state law to offer a peer-to-peer review within 2 business days of a request. Your HealthRX provider can conduct that peer-to-peer call. Approval rates after peer-to-peer review for PCSK9 inhibitors nationally run approximately 45-60%, based on the 2023 IQVIA analysis of specialty biologic PA appeals [12].

Wyoming Medicaid and Coverage Gaps

Wyoming Medicaid does not cover Repatha as of July 2025. The Wyoming Department of Health's preferred drug list excludes all PCSK9 inhibitors for both the HeFH and ASCVD indications [13]. Medicaid-enrolled patients in Wyoming have two primary options.

Amgen's REPATHA PATHWAYS program offers $0 copay for commercially insured patients, and a free-medication program for uninsured or underinsured patients who meet income criteria (household income at or below 600% of federal poverty level). Applications are processed at 1-844-REPATHA or via Amgen's online portal. The free-drug program typically ships a 3-month supply every 90 days.

Alternative PCSK9 inhibitor consideration. Alirocumab (Praluent, Sanofi/Regeneron) carries the same indication set and a similar mechanism. If one PCSK9 inhibitor is excluded from formulary or denied on PA, the other may not be, giving Wyoming patients a second pathway to PCSK9 inhibition. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% relative to placebo over a median 2.8 years in post-ACS patients [14].

Transferring an Existing Repatha Prescription to Wyoming

Patients relocating to Wyoming who already have an established Repatha prescription from another state can continue therapy without interruption, provided their specialty pharmacy ships to Wyoming addresses. Most national specialty pharmacies (CVS Specialty, Accredo, Walgreens Specialty) do ship to Wyoming.

However, the original prescriber must be licensed in Wyoming to remain the prescriber of record, or the patient must establish care with a Wyoming-licensed provider. A telehealth visit with a Wyoming-licensed HealthRX clinician achieves that transfer in a single appointment. Bring the prior prescriber's note, your PA approval letter, and your most recent lipid panel. The new provider can issue a new prescription and file a PA transfer (or a fresh PA if your insurer requires) without restarting the clinical justification process from scratch.

The original out-of-state PA approval is not automatically valid in Wyoming. Insurers treat a change of prescriber or dispensing pharmacy as a triggering event for a new PA in approximately 38% of cases, based on the 2022 AMCP Foundation survey of specialty pharmacy transitions [15].

503A Pharmacy Access for Evolocumab in Wyoming

Wyoming-licensed 503A compounding pharmacies are legally permitted to prepare patient-specific compounded preparations, including monoclonal antibody analogs, when prescribed by a licensed Wyoming provider for a specific patient under the federal 503A exemption to the FDCA [16]. This pathway exists primarily for patients with specific delivery-device needs or documented ingredient sensitivities to Repatha's excipients (polysorbate 80 or proline).

Compounded evolocumab is not bioequivalent-tested against the FDA-approved product and is not subject to the same manufacturing oversight. The FDA has not approved any compounded PCSK9 inhibitor. Patients and prescribers should treat 503A compounding as a last-resort alternative, not a substitute for FDA-approved Repatha when the branded product is accessible.

Wyoming's State Board of Pharmacy maintains a license-verification portal where patients can confirm a 503A pharmacy's standing before dispensing [17]. Any 503A compounding pharmacy shipping evolocumab into Wyoming must hold an active Wyoming nonresident pharmacy permit.

Dosing, Administration, and Monitoring After Starting Repatha

The FDA-approved dosing options are 140 mg subcutaneously every 2 weeks (SureClick autoinjector or single-use prefilled syringe) or 420 mg subcutaneously once monthly (single-use on-body infusor over 9 minutes) [1]. The 420 mg monthly dose requires three consecutive 140 mg injections at separate sites within 30 minutes or use of the Pushtronex on-body infusor.

Patients self-administer after training. The injection sites are the abdomen (at least 2 inches from the navel), thigh, or upper arm. Rotate sites with each injection. Store Repatha in the refrigerator at 36-46°F (2-8°C); it can be kept at room temperature below 77°F for up to 30 days once removed from the refrigerator [1].

Monitoring after initiation follows the National Lipid Association 2023 guidance [6]:

• Lipid panel at 4-12 weeks after starting to confirm LDL-C response. A response of at least 50% reduction from baseline confirms adequate PCSK9 inhibition.
• Repeat lipid panel every 3-12 months during stable therapy.
• No routine liver enzyme monitoring is required by the FDA label, unlike statin therapy. CMP monitoring is driven by comorbidities rather than evolocumab itself.

In FOURIER, the most common adverse effects were nasopharyngitis (10.5% vs. 10.3% placebo), injection-site reactions (2.1% vs. 1.6% placebo), and influenza (7.4% vs. 7.4% placebo), none of which were statistically distinguishable from placebo rates [3]. Neurocognitive adverse effects were studied in the EBBINGHAUS sub-study (N=1,974) and showed no significant difference between evolocumab and placebo on executive function or memory at 19 months [18].